JP2024537284A5 - - Google Patents
Info
- Publication number
- JP2024537284A5 JP2024537284A5 JP2024521784A JP2024521784A JP2024537284A5 JP 2024537284 A5 JP2024537284 A5 JP 2024537284A5 JP 2024521784 A JP2024521784 A JP 2024521784A JP 2024521784 A JP2024521784 A JP 2024521784A JP 2024537284 A5 JP2024537284 A5 JP 2024537284A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- use according
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163254447P | 2021-10-11 | 2021-10-11 | |
| US63/254,447 | 2021-10-11 | ||
| PCT/US2022/077908 WO2023064769A1 (en) | 2021-10-11 | 2022-10-11 | Methods of effecting a hemodynamic change by administering an anti-npr1 antibody |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024537284A JP2024537284A (ja) | 2024-10-10 |
| JP2024537284A5 true JP2024537284A5 (enExample) | 2025-12-22 |
Family
ID=84045029
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024521784A Pending JP2024537284A (ja) | 2021-10-11 | 2022-10-11 | 抗ｎｐｒ１抗体を投与することにより血行動態の変化を引き起こす方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20240327539A1 (enExample) |
| EP (1) | EP4415820A1 (enExample) |
| JP (1) | JP2024537284A (enExample) |
| KR (1) | KR20240099275A (enExample) |
| CN (1) | CN118159290A (enExample) |
| AU (1) | AU2022363841A1 (enExample) |
| CA (1) | CA3234238A1 (enExample) |
| CL (1) | CL2024001071A1 (enExample) |
| CO (1) | CO2024005662A2 (enExample) |
| IL (1) | IL311917A (enExample) |
| MX (1) | MX2024004302A (enExample) |
| WO (1) | WO2023064769A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024542823A (ja) | 2021-12-06 | 2024-11-15 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | アンタゴニスト抗ｎｐｒ１抗体およびその使用方法 |
| AU2024287056A1 (en) * | 2023-06-08 | 2025-12-11 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-npr1 antibody and pharmaceutical use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| WO2010065293A1 (en) | 2008-12-03 | 2010-06-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Antibodies for guanylyl cyclase receptors |
| KR20210082207A (ko) | 2018-10-23 | 2021-07-02 | 리제너론 파아마슈티컬스, 인크. | 항-npr1 항체 및 이의 용도 |
| US11066469B2 (en) * | 2019-06-12 | 2021-07-20 | Novartis Ag | Natriuretic peptide receptor 1 antibodies and methods of use |
| US12325752B2 (en) * | 2020-12-18 | 2025-06-10 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to NPR1 agonists |
-
2022
- 2022-10-11 CN CN202280068577.9A patent/CN118159290A/zh active Pending
- 2022-10-11 US US18/045,671 patent/US20240327539A1/en not_active Abandoned
- 2022-10-11 CA CA3234238A patent/CA3234238A1/en active Pending
- 2022-10-11 AU AU2022363841A patent/AU2022363841A1/en active Pending
- 2022-10-11 KR KR1020247015704A patent/KR20240099275A/ko active Pending
- 2022-10-11 MX MX2024004302A patent/MX2024004302A/es unknown
- 2022-10-11 IL IL311917A patent/IL311917A/en unknown
- 2022-10-11 WO PCT/US2022/077908 patent/WO2023064769A1/en not_active Ceased
- 2022-10-11 JP JP2024521784A patent/JP2024537284A/ja active Pending
- 2022-10-11 EP EP22798040.6A patent/EP4415820A1/en active Pending
-
2024
- 2024-04-10 CL CL2024001071A patent/CL2024001071A1/es unknown
- 2024-04-30 CO CONC2024/0005662A patent/CO2024005662A2/es unknown
- 2024-10-11 US US18/913,899 patent/US20250034279A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2361917T3 (es) | Inhibidores del receptor 1 del factor de crecimiento de fibroblastos y procedimiento de tratamiento de los mismos. | |
| DK1976886T3 (en) | Means and methods for the treatment of tumor diseases | |
| US20230203202A1 (en) | Proteins binding nkg2d, cd16 and 5t4 | |
| TW201023855A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan | |
| CN117222663A (zh) | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 | |
| CN114558129A (zh) | 用于降低心血管风险的方法 | |
| JP2022505604A5 (enExample) | ||
| RU2014106652A (ru) | Ингибирующие моноклональные антитела против фактора xii/xiia и их применения | |
| JP2024537284A5 (enExample) | ||
| NO20170737A1 (no) | Anvendelse av anti-CD3 antistoff for fremstilling av et medikament mot aterosklerose, samt et anti-CD3 antistoff | |
| JP2018515513A (ja) | 多発性骨髄腫（ｍｍ）の処置 | |
| JP2023155262A (ja) | プレクチン１結合抗体およびその使用 | |
| JP2025509304A5 (enExample) | ||
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| JP5068253B2 (ja) | 心臓血管疾患の治療 | |
| US20210403573A1 (en) | Methods and pharmaceutical compositions for the treatment of fibrosis with agents capable of inhibiting the activation of mucosal-associated invariant t (mait) cells | |
| JP2023507795A5 (enExample) | ||
| JP2024542823A5 (enExample) | ||
| JP2024537284A (ja) | 抗ｎｐｒ１抗体を投与することにより血行動態の変化を引き起こす方法 | |
| JP2024500322A (ja) | 併用療法 | |
| WO2025134049A1 (en) | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis | |
| WO2025134050A1 (en) | Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma | |
| JP2024177399A (ja) | 呼吸器疾患の治療のための汎ｅｌｒ＋ｃｘｃケモカイン抗体 | |
| EP3362088A1 (en) | An agent capable of depleting cd8 t cells for the treatment of myocardial infarction or acute myocardial infarction | |
| JP2024507986A5 (enExample) |